Targeting hyperapoB vs normoapoB to reduce the risk of type 2 diabetes in obese subjects; mechanism of action

相对于normoapoB，靶向hyperapoB可降低肥胖受试者患2型糖尿病的风险；

• 批准号: 172911
• 负责人: Faraj May
• 金额: $ 29.5万
• 依托单位: Universit de Montral
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-09-01 至 2011-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=172911&lang=en
• 关键词: 24 Weeks Hypocaloric Diet Intervention; Blood & Adipose Tissue); Fatty Acid Trapping (In Vivo & Ex Vivo In Adipose Tissue); Inflammation (In Vivo & Ex Vivo; Insulin Sensitivity (In Vivo & Ex Vivo In Adipose Tissue); Lipids & Apob-Lipoproteins (Size; Numbe

Background: Type 2 diabetes results in the yearly death of ~ 40,000 Canadians. Some obese subjects have higher risk to develop diabetes and my research will examine why. The risk for type 2 diabetes in obese subjects increases when the body is resistance

背景：加拿大每年约有40000人死于2型糖尿病。一些肥胖的人患糖尿病的风险更高，我的研究将探究其中的原因。肥胖者患2型糖尿病的风险在身体抵抗时增加